NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

CVS Health (NYSE:CVS) on Thursday announced plans ... to improve access to the Danish drugmaker’s popular weight loss drug Wegovy. Accordingly, in a market where Eli Lilly’s (LLY) also ...

Shares of CVS Health Corp. soared toward a one-year high ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...

CVS Health’s insurance division Aetna will stop ... with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary, which covers ...

Citing CVS spokesperson David Whitrap, Bloomberg News reported that “Zepbound will be excluded” in health plans using ... in those plans could switch to Wegovy, while exceptions will be ...

This will enable CVS Pharmacy to provide eligible patients at its 9,000 community health locations with convenient, safe, and affordable access to Novo Nordisk A/S' NVO Wegovy. Guidance ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... while membership increased by 1.1%. For health services, which include CVS Caremark, revenue increased 7.9% to $43.46 billion ...